Unknown

Dataset Information

0

Olmesartan alleviates SARS-CoV-2 envelope protein induced renal fibrosis by regulating HMGB1 release and autophagic degradation of TGF-β1.


ABSTRACT: Background and aims: Renal damage in severe coronavirus disease 2019 (COVID-19) is highly associated with mortality. Finding relevant therapeutic candidates that can alleviate it is crucial. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) have been shown to be harmless to COVID-19 patients, but it remains elusive whether ACEIs/ARBs have protective benefits to them. We wished to determine if ACEIs/ARBs had a protective effect on the renal damage associated with COVID-19, and to investigate the mechanism. Methods: We used the envelope (E) protein of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) to induce COVID-19-like multiple organ damage and observed renal fibrosis. We induced the epithelial-mesenchymal transformation of HK-2 cells with E protein, and found that olmesartan could alleviate it significantly. The protective effects of olmesartan on E protein-induced renal fibrosis were evaluated by renal-function assessment, pathologic alterations, inflammation, and the TGF-β1/Smad2/3 signaling pathway. The distribution of high-mobility group box (HMGB)1 was examined after stimulation with E protein and olmesartan administration. Results: E protein stimulated HMGB1 release, which triggered the immune response and promoted activation of TGF-β1/Smad2/3 signaling: both could lead to renal fibrosis. Olmesartan regulated the distribution of HMGB1 under E protein stimulation. Olmesartan inhibited the release of HMGB1, and reduced the inflammatory response and activation of TGF-β1/Smad2/3 signaling. Olmesartan increased the cytoplasmic level of HMGB1 to promote the autophagic degradation of TGF-β1, thereby alleviating fibrosis further. Conclusion: Olmesartan alleviates E protein-induced renal fibrosis by regulating the release of HMGB1 and its mediated autophagic degradation of TGF-β1.

SUBMITTER: Zhou S 

PROVIDER: S-EPMC10225711 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Olmesartan alleviates SARS-CoV-2 envelope protein induced renal fibrosis by regulating HMGB1 release and autophagic degradation of TGF-β1.

Zhou Shilin S   Yu Zanzhe Z   Chen Zihui Z   Ning Fengling F   Hu Xuetao X   Wu Tiangang T   Li Mingxue M   Xin Hong H   Reilly Svetlana S   Zhang Xuemei X  

Frontiers in pharmacology 20230515


<b>Background and aims:</b> Renal damage in severe coronavirus disease 2019 (COVID-19) is highly associated with mortality. Finding relevant therapeutic candidates that can alleviate it is crucial. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) have been shown to be harmless to COVID-19 patients, but it remains elusive whether ACEIs/ARBs have protective benefits to them. We wished to determine if ACEIs/ARBs had a protective effect on the renal damage as  ...[more]

Similar Datasets

| S-EPMC10606262 | biostudies-literature
| S-EPMC9649626 | biostudies-literature
2025-05-29 | GSE266409 | GEO
| S-EPMC11257276 | biostudies-literature
| S-EPMC6286536 | biostudies-literature
| S-EPMC4157079 | biostudies-literature
| S-EPMC11505648 | biostudies-literature
| S-EPMC11906606 | biostudies-literature
| S-EPMC4544629 | biostudies-literature
| S-EPMC6561928 | biostudies-literature